-

Harrow to Present at Two Investor Conferences in May

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:

B. Riley Securities 25th Annual Investor Conference (The Ritz-Carlton, Marina del Rey, CA)
Format: Fireside Chat, followed by 1x1 Investor Meetings
Date/Time: Wednesday, May 21, 2025, through Thursday, May 22, 2025

Craig-Hallum 22nd Annual Institutional Investor Conference (Depot Renaissance Hotel, Minneapolis, MN)
Format: 1x1 and Small Group Investor Meetings
Date/Time: Wednesday, May 28, 2025

Investors interested in meeting with management during either conference should contact their B. Riley or Craig-Hallum representative to request a meeting. Neither event will be webcast.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

Contacts

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

Industry:

Harrow, Inc.

NASDAQ:HROW
Release Versions
English
$Cashtags
$HROW

Contacts

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

More News From Harrow, Inc.

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

NASHVILLE, Tenn. & TAIPEI, Taiwan--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain...

Harrow Announces First-Quarter 2025 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2025. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations f...

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Friday, May 9, 2025, to disc...
Back to Newsroom